Literature DB >> 33859795

Discovery of 2,4-1H-Imidazole Carboxamides as Potent and Selective TAK1 Inhibitors.

Johan J N Veerman1, Yorik B Bruseker2, Eddy Damen2, Erik H Heijne2, Wendy van Bruggen2, Koen F W Hekking2, Rob Winkel2, Christopher D Hupp3, Anthony D Keefe3, Julie Liu4, Heather A Thomson3, Ying Zhang3, John W Cuozzo3, Andrew J McRiner3, Mark J Mulvihill5, Peter van Rijnsbergen2, Birgit Zech6, Louis M Renzetti7, Lee Babiss8, Gerhard Müller6.   

Abstract

Herein we report the discovery of 2,4-1H-imidazole carboxamides as novel, biochemically potent, and kinome selective inhibitors of transforming growth factor β-activated kinase 1 (TAK1). The target was subjected to a DNA-encoded chemical library (DECL) screen. After hit analysis a cluster of compounds was identified, which was based on a central pyrrole-2,4-1H-dicarboxamide scaffold, showing remarkable kinome selectivity. A scaffold-hop to the corresponding imidazole resulted in increased biochemical potency. Next, X-ray crystallography revealed a distinct binding mode compared to other TAK1 inhibitors. A benzylamide was found in a perpendicular orientation with respect to the core hinge-binding imidazole. Additionally, an unusual amide flip was observed in the kinase hinge region. Using structure-based drug design (SBDD), key substitutions at the pyrrolidine amide and the glycine resulted in a significant increase in biochemical potency.
© 2021 American Chemical Society.

Entities:  

Year:  2021        PMID: 33859795      PMCID: PMC8040042          DOI: 10.1021/acsmedchemlett.0c00547

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  33 in total

1.  TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway.

Authors:  G Takaesu; S Kishida; A Hiyama; K Yamaguchi; H Shibuya; K Irie; J Ninomiya-Tsuji; K Matsumoto
Journal:  Mol Cell       Date:  2000-04       Impact factor: 17.970

2.  Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.

Authors:  Davide Melisi; Qianghua Xia; Genni Paradiso; Jianhua Ling; Tania Moccia; Carmine Carbone; Alfredo Budillon; James L Abbruzzese; Paul J Chiao
Journal:  J Natl Cancer Inst       Date:  2011-07-08       Impact factor: 13.506

Review 3.  TAK1 control of cell death.

Authors:  S R Mihaly; J Ninomiya-Tsuji; S Morioka
Journal:  Cell Death Differ       Date:  2014-08-22       Impact factor: 15.828

4.  The identification of novel p38α isoform selective kinase inhibitors having an unprecedented p38α binding mode.

Authors:  Stephen T Wrobleski; Shuqun Lin; T G Murali Dhar; Alaric J Dyckman; Tianle Li; Sidney Pitt; Rosemary Zhang; Yi Fan; Arthur M Doweyko; John S Tokarski; Kevin F Kish; Susan E Kiefer; John S Sack; John A Newitt; Mark R Witmer; Murray McKinnon; Joel C Barrish; John H Dodd; Gary L Schieven; Katerina Leftheris
Journal:  Bioorg Med Chem Lett       Date:  2013-05-23       Impact factor: 2.823

5.  Development of a Method for Converting a TAK1 Type I Inhibitor into a Type II or c-Helix-Out Inhibitor by Structure-Based Drug Design (SBDD).

Authors:  Terushige Muraoka; Mitsuaki Ide; Machiko Irie; Kenji Morikami; Takaaki Miura; Masamichi Nishihara; Hirotaka Kashiwagi
Journal:  Chem Pharm Bull (Tokyo)       Date:  2016       Impact factor: 1.645

Review 6.  Ubiquitin-mediated activation of TAK1 and IKK.

Authors:  A Adhikari; M Xu; Z J Chen
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

Review 7.  MAP kinase signalling pathways in cancer.

Authors:  A S Dhillon; S Hagan; O Rath; W Kolch
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

8.  Inhibition of ovarian cancer cell growth by a novel TAK1 inhibitor LYTAK1.

Authors:  Liu Ying; Yin Chunxia; Liu Wei
Journal:  Cancer Chemother Pharmacol       Date:  2015-07-31       Impact factor: 3.333

9.  A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase.

Authors:  Jun Ninomiya-Tsuji; Taisuke Kajino; Koichiro Ono; Toshihiko Ohtomo; Masahiko Matsumoto; Masashi Shiina; Masahiko Mihara; Masayuki Tsuchiya; Kunihiro Matsumoto
Journal:  J Biol Chem       Date:  2003-03-06       Impact factor: 5.486

10.  TAK1 inhibitor NG25 enhances doxorubicin-mediated apoptosis in breast cancer cells.

Authors:  Zhenyu Wang; Huiyuan Zhang; Minghao Shi; Yang Yu; Hao Wang; Wen-Ming Cao; Yanling Zhao; Hong Zhang
Journal:  Sci Rep       Date:  2016-09-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.